Biosimilars And Biosuperiors Therapeutics Antibodies In-Depth Industrial and Market studies - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2017 - 2019
Albany, New York, Feb 03, 2017
"Biosimilars
And Biosuperiors Therapeutics Antibodies Market - Global Industry
Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2019"
The Report covers current Industries Trends, Worldwide Analysis,
Global Forecast, Review, Share, Size, Growth, Effect.
Description-
A
biosimilar medicine possesses the similar pharmacokinetic and mode of
action as an original biological medicine that has already been
approved for therapeutic use. Biosimilars are made from a living
organism such as bacteria and yeast or can also be derived from small
molecules like human insulin, erythropoietin and monoclonal
antibodies via recombinant DNA and gene expression technologies.
Biosimilars
are developed only when original biological medicines are
commercially expired and therefore are known as follow on biologics
or subsequent entry biologics. These molecules are used to treat same
diseases as original molecules intended to. Like biosimilars,
biosuperiors are also developed against already approved biological
medicines but they possess attributes that are superior to the
original molecules and not only replication. Biosuperiors are
developed by utilizing revolutionary technologies including protein
engineering, effector function enhancement, half-life extension
through Fc engineering, bispecific molecules, antibody-drug conjugate
technology and affinity maturation which enable biosuperiors with
improved attributes over their innovator molecules.
Developing
a new biological medicine can incur cost up to USD 1.2 billion that
is also associated with a high risk of research and development
failure. However, the overall cost and research and development risk
with biosimilars and biosuperiors are less than the original
biologics. By some estimates, from development to approval, a
biosimilar may incur cost up to USD 75 million to USD 250 million. On
account of a requisite of lower investment many pharmaceutical and
biopharmaceutical companies are striving to enter into biosimilars
and biosuperiors market. One such example is Medlmmune, a business
unit of AstraZeneca plc that has increased its investment in research
and development programs related with biosuperiors with an intention
to maintain a clinical pipeline portfolio with minimal risk. They
consider biosimilars and biosuperiors, new drug categories with
immense opportunities and expect to get higher return on little
investment. This indicates a favorable condition for biosimilars and
biosuperiors therapeutic antibodies market to grow. Advances in
technology such as polyclonal mixtures, Fc engineering and
antibody-drug conjugate also drive the market growth by escalating
research and development activities.
The
low price for biosimilars which usually costs in a range of 65%-75%
of its original biological medicines is one of the key factors
driving the demand for biosimilars worldwide. Biosimilars being cost
effective alternative to innovator products also attract government
and many payers, indicates a positive growth of the molecule.
Patent
expiry of many blockbuster biologics in coming years is expected to
intensify the competition among biosimilar and biosuperiors
manufacturers. It is estimated that by 2020, many biologics with
sales worth of USD 81 billion are expected to lose their exclusivity.
These biologics include Avastin (bevacizumab), Herceptin
(trastuzumab), Synagis (palivizumab), Enbrel (etanercept), Humira
(adalimimab), Remicade (infliximab) and Rituxan (rituximab). These
patent expiries of major biologics are expected to offer potential
opportunities in North America as well as Europe. In Asia-Pacific
region, low cost of biosimilars and biosuperiors will play a key role
in driving the market growth as reimbursement scenario in the region
is very poor and patients have to pay for the drugs from their own
pocket only. A large pool of patient with various chronic diseases
including lung cancer and prostate cancer will further drive the
market growth in Asia-Pacific region.
AstraZeneca
plc, Eli Lilly and Company, Bristol-Myers Squibb, GlaxoSmithKline,
Amgen, Inc., Novo Nordisk, Abbott Laboratories, Sanofi and Novartis
AG are some major companies operating in the market for biosimilars
and biosuperiors therapeutics antibodies.
–
This research report analyzes this market depending on its
market segments, major geographies, and current market trends.
Geographies analyzed under this research report include
- North America
- Asia Pacific
- Europe
- Rest of the World
– This report provides comprehensive
analysis of
- Market growth drivers
- Factors limiting market growth
- Current market trends
- Market structure
- Market projections for upcoming years
This report is a
complete study of current trends in the market, industry growth
drivers, and restraints. It provides market projections for the
coming years. It includes analysis of recent developments in
technology, Porter’s five force model analysis and detailed
profiles of top industry players. The report also includes a review
of micro and macro factors essential for the existing market players
and new entrants along with detailed value chain analysis.
– Reasons for Buying this Report
- This report provides pin-point analysis for changing competitive dynamics
- It provides a forward looking perspective on different factors driving or restraining market growth
- It provides a technological growth map over time to understand the industry growth rate
- It provides a seven-year forecast assessed on the basis of how the market is predicted to grow
- It helps in understanding the key product segments and their future
- It provides pin point analysis of changing competition dynamics and keeps you ahead of competitors
- It helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments
- It provides distinctive graphics and exemplified SWOT analysis of major market segments
Comments
Post a Comment